ChAdOx1 nCoV-19: all 27 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised AdultsTerminatedNCT05057897Phase 4Results posted
• Phase II/III Study of AZD2816, for the Prevention of COVID-19 in AdultsCompletedNCT04973449Phase 2/3Results posted
• Study of AZD1222 for the Prevention of COVID-19 in JapanCompletedNCT04568031Phase 1/2Results posted
• Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in AdultsCompletedNCT04516746Phase 3Results posted
• Immunogenicity After COVID-19 Vaccines in Adapted SchedulesCompletedNCT06189040Phase 4
• Incidence of COVID-19 Following Vaccination in Botswana Against SARS CoV 2CompletedNCT05715944Phase 3
• Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster DoseCompletedNCT05567471Phase 3
• Evaluation of COVID-19 Vaccines Given as a Booster in Healthy Adults in Indonesia (MIACoV Indonesia)WithdrawnNCT05387317Phase 3
• Immunogenicity and Safety of Fractional Booster Dose of COVID-19 Vaccines Available for Use in Pakistan/Brazil: A Phase 4 Dose-optimizing TrialCompletedNCT05343871Phase 4
• A Study to Evaluate the Safety and Immunogenicity of Booster With AZD1222, mRNA-1273, or MVC-COV1901 Against COVID-19CompletedNCT05197153Phase 2
• COVID-19 VACCINE SAFETY AND EFFECTIVENESSStatus unknownNCT05133609Phase 1/2
• Efficacy and Safety of Heterologous and Homologous COVID-19 VaccinationCompletedNCT05074368Not applicable
• EFFECTIVENESS, SAFETY AND IMMUNOGENICITY OF THE HALF DOSE OF THE VACCINE ChadOx1 nCoV-19 (AZD1222) for COVID-19Status unknownNCT05059106Phase 2/3
• A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in AdultsCompletedNCT05011526Phase 3
• Effectiveness of Covid-19 Vaccination in Eswatini Against SARS-CoV-2 Associated Hospitalization and DeathCompletedNCT04914832Phase 4
• Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2Status unknownNCT04907331Phase 2
• A Study of Intranasal ChAdOx1 nCOV-19CompletedNCT04816019Phase 1
• Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver CirrhosisStatus unknownNCT04794946Not applicable
• Antibody Response to COVID-19 Vaccines in Liver Disease PatientsCompletedNCT04775069Phase 4
• Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)CompletedNCT04760730Phase 1/2
• National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE)CompletedNCT04760132Phase 4
• Open-label, Non-randomized, Non-comparative, Phase II Study of Safety and Immunogenicity of Combination of AZD1222 and rAd26-S for COVID-19 PreventionCompletedNCT04686773Phase 2
• Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime-Boost Regimen for the Prevention of COVID-19CompletedNCT04684446Phase 1/2
• AZD1222 Vaccine for the Prevention of COVID-19WithdrawnNCT04540393Phase 3
• COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infectionStatus unknownNCT04444674Phase 1/2
• Investigating a Vaccine Against COVID-19CompletedNCT04400838Phase 2/3
• A Study of a Candidate COVID-19 Vaccine (COV001)CompletedNCT04324606Phase 1/2

← ChAdOx1 nCoV-19 overview